GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a prefilled syringe ...

London: GSK plc has received approval from the US Food and Drug Administration (FDA) for a prefilled syringe presentation of ...

GSK PLC closed 16.45% short of its 52-week high of £16.79, which the company reached on September 9th.

(Alliance News) - GSK PLC on Thursday said the prefilled syringe version of its vaccine Shingrix has been approved for use in the US for the prevention of shingles.

GSK PLC closed 15.32% short of its 52-week high of £16.79, which the company reached on September 9th.

London: GSK plc has announced that the US Food and Drug Administration (FDA) has accepted for review an application to extend ...

FDA reviewers said in briefing documents that the benefit-risk profile of the drug for the treatment of multiple myeloma “remains unclear.” ...

GSK plc (NYSE:GSK) reported solid financial results for fiscal Q4 2024, reflecting strong growth across key metrics. Its sales grew 8% to over £31 billion in 2024, and core operating profit rose ...

We recently compiled a list of the 10 Companies Jump on Better Earnings, Outlook. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The ...

GSK said it now expects adjusted operating profit to increase between 13-15% for the year after it reported a rise in net profit in the third quarter, mainly due to the U.S. launch of its Arexvy ...

The U.S. FDA has approved a prefilled syringe presentation of GSK plc’s SHINGRIX for the prevention of shingles.